Acral Melanoma Cell Line Series BioVector® 肢端黑色素瘤细胞系

• 系列概况： 肢端黑色素瘤 (Acral Melanoma, AM) 是一种起源于手掌、足底或指甲床等无毛皮肤区域的特殊黑色素瘤亚型。由于其遗传背景（如较低的 UV 突变负荷和较高的结构变异）与皮肤黑色素瘤显著不同，该系列细胞系是研究亚洲人群高发黑色素瘤的关键模型。

• 物种： 人 (Homo sapiens)。

• 代表性型号：

  • BioVector® AM-A375/AM-Luc： 经过工程化改造用于体内成像。

  • BioVector® SKU-MEL 系列或患者来源系 (如来自 Fudan University 或 Peking University Cancer Hospital 的 PDX 衍生系)。

  
  

• 共有遗传特征：

  • 驱动突变： 常见 KIT 扩增/突变、CCND1 扩增、CDKN2A 缺失；BRAF 突变频率远低于普通黑色素瘤。

  • 染色体不稳定： 表现为复杂的基因组重排和拷贝数变异 (CNA)。

  
  

• 培养指南：

  • 培养基： 90% RPMI 1640 或 DMEM + 10% 胎牛血清 (FBS) + 1% P/S。

  • 生长特性： 贴壁生长，黑色素含量差异较大。

  
  

• 主要应用：KIT 抑制剂 药敏筛选、肢端黑色素瘤免疫治疗耐药研究、以及染色体断裂融合循环 (BFB) 机制研究。

BioVector® Acral Melanoma Cell Line Series

• Series Overview: Acral Melanoma (AM) is a distinct subtype of melanoma arising from non-hair-bearing skin (palms, soles, nail beds). Unlike cutaneous melanoma, AM has a low UV-signature mutational burden and high structural genomic variations, making these BioVector® lines essential for studying this Asian-prevalent malignancy.

• Species: Human (Homo sapiens).

• Representative Models:

  • BioVector® AM-derived lines: Including patient-derived xenograft (PDX) stable lines established by institutions like the Peking University Cancer Hospital.

  
  

• Genomic Profile:

  • Driver Mutations: Frequently feature KIT mutations/amplification, CCND1 amplification, and CDKN2A loss. BRAF mutations are significantly less common than in cutaneous subtypes.

  • Genomic Instability: Characterized by complex structural variations and copy number alterations (CNA).

  
  

• Cell Culture Data:

  • Medium: 90% RPMI 1640 or DMEM + 10% Fetal Bovine Serum (FBS) + 1% Pen/Strep.

  • Growth: Adherent; melanin production varies by line.

  
  

• Applications: Screening for KIT-targeted inhibitors, investigating resistance to PD-1/CTLA-4 immunotherapy, and modeling chromosome instability.

Supplier生产厂家:

BioVector NTCC质粒载体菌种细胞蛋白抗体基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947

E-mail: biovector@163.com

工作微信/QQ同号: 1843439339

http://www.biovector.net